Izencitinib clinical trials
Also written TD-1473.
How each study uses izencitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Studies
Open first, then newest update. How each study uses izencitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Efficacy and Safety of TD-1473 in Crohn's DiseaseTerminatedPhase 2Theravance BiopharmaNCT03635112Written as TD-1473How we know
- Efficacy & Safety of TD-1473 in Ulcerative ColitisTerminatedPhase 2/3Theravance BiopharmaNCT03758443Written as TD-1473 Dose AHow we know
- TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) StudyTerminatedPhase 2/3Theravance BiopharmaNCT03920254Written as TD-1473 Dose AHow we know
- TD-1473 for Active Ulcerative Colitis (UC)CompletedPhase 1Theravance BiopharmaNCT02818686Written as TD-1473How we know
- Single Dose Bioavailability and Ethnobridging PK Study in Healthy SubjectsCompletedPhase 1Theravance BiopharmaNCT04587713Written as TD-1473 [Tablet A]How we know
- SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy SubjectsCompletedPhase 1Theravance BiopharmaNCT02657122Written as TD-1473 for SADHow we know
- Multiple Dose Ethnobridging PK Study in Healthy SubjectsCompletedPhase 1Theravance BiopharmaNCT03750565Written as TD-1473 - Dose AHow we know
- Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging StudyCompletedPhase 1Theravance BiopharmaNCT03555617Written as TD-1473How we know
- TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male SubjectsCompletedPhase 1Theravance BiopharmaNCT03408470Written as TD-1473 oral capsuleHow we know
Codes
What other systems call izencitinib · ClinicalTrials.gg INT001677
- MeSH (NLM) C000718529izencitinibOne source NLM
- UNII (FDA) 2ZT81PV5UMIZENCITINIBConfirmed FDA, NLM
- NCI Thesaurus C175805IzencitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718529 | izencitinib | One source NLM |
| UNII (FDA) | 2ZT81PV5UM | IZENCITINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C175805 | Izencitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.